Exelixis, Inc. (EXEL)

Market Cap	9.51B
Revenue (ttm)	2.08B
Net Income (ttm)	466.92M
Shares Out	285.58M
EPS (ttm)	1.55
PE Ratio	21.51
Forward PE	18.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,320,571
Open	33.30
Previous Close	33.68
Day's Range	33.11 - 33.68
52-Week Range	19.20 - 36.97
Beta	0.52
Analysts	Buy
Price Target	32.75 (-1.62%)
Earnings Date	Feb 4, 2025

About EXEL

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2000
• Employees: 1,310
• Stock Exchange: NASDAQ
• Ticker Symbol: EXEL
• Website: https://www.exelixis.com

Financial Performance

In 2023, Exelixis's revenue was $1.83 billion, an increase of 13.60% compared to the previous year's $1.61 billion. Earnings were $207.77 million, an increase of 13.98%.

Analyst Forecast

According to 16 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price forecast is $32.75, which is a decrease of -1.62% from the latest price.

Price Target

$32.75

(-1.62% downside)

Analyst Consensus: Buy